MACROGENICS
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.
MACROGENICS
Industry:
Biotechnology Health Care Manufacturing
Founded:
2000-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.macrogenics.com
Total Employee:
501+
Status:
Active
Contact:
3012515321
Total Funding:
165.92 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
2008-07-01
Board_member
Board_member
2013-09-01
Current Employees Featured
Heather Preston Observer of Boards @ MacroGenics
Observer of Boards
Alan Aderem Co-Founder @ MacroGenics
Co-Founder
Eric Risser Chief Operating Officer @ MacroGenics
Chief Operating Officer
2022-02-01
Lynn Cilinski Vice President, Controller and Treasurer @ MacroGenics
Vice President, Controller and Treasurer
Leroy Hood Co-Founder @ MacroGenics
Co-Founder
Ezio Bonvini Chief Scientific Officer @ MacroGenics
Chief Scientific Officer
2003-06-01
Scott Koenig President & Chief Executive Officer and Board Member @ MacroGenics
President & Chief Executive Officer and Board Member
2001-09-01
Tom Spitznagel Senior Vice President, BioPharmaceutical Development and Manufacturing @ MacroGenics
Senior Vice President, BioPharmaceutical Development and Manufacturing
James Karrels Senior Vice President, Chief Financial Officer @ MacroGenics
Senior Vice President, Chief Financial Officer
2008-05-01
Harish Krishnaswamy Sr. Director Of Business Development @ MacroGenics
Sr. Director Of Business Development
2018-10-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2008-07-17 | Raven Biotechnologies | Raven Biotechnologies acquired by MacroGenics | N/A |
| 2002-06-07 | Eliance Biotechnology | Eliance Biotechnology acquired by MacroGenics | N/A |
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - MacroGenics
Nextech Venture
Nextech Venture investment in Series D - MacroGenics
Eli Lilly & Company Foundation
Eli Lilly & Company Foundation investment in Series D - MacroGenics
Mitsubishi UFJ
Mitsubishi UFJ investment in Series D - MacroGenics
Arcus Ventures
Arcus Ventures investment in Series D - MacroGenics
TPG
TPG investment in Series D - MacroGenics
Innovis Investments
Innovis Investments investment in Series D - MacroGenics
Alta Partners
Alta Partners investment in Series D - MacroGenics
Ventures West
Ventures West investment in Series D - MacroGenics
CIDC Consultants
CIDC Consultants investment in Series D - MacroGenics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-28 | MacroGenics Announces Executive Promotion |
Official Site Inspections
http://www.macrogenics.com Semrush global rank: 3.54 M Semrush visits lastest month: 4.15 K
- Host name: 77.113.185.35.bc.googleusercontent.com
- IP address: 35.185.113.77
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "MacroGenics"
MacroGenics, Inc. - LinkedIn
MacroGenics' corporate culture promotes an atmosphere of innovation, open communication and teamwork where employees can see firsthand how they contribute to the success of the organization. WebsiteSee details»
MacroGenics - Crunchbase Company Profile & Funding
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune …See details»
About Us - MacroGenics
MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of …See details»
MacroGenics – Developing innovative antibody-based cancer …
We are a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.See details»
MacroGenics, Inc. Information - RocketReach
MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies. Our team of 300+ dedicated individuals is …See details»
Our Living Values - MacroGenics
The following list of our living values reflects what is most important to us as an organization and drives all that we do. We are unwavering in our commitment to these values, which represent …See details»
MacroGenics Corporate Overview - 2017-11-10 Post-3Q CALL
• Integrated, highly productive R&D organization Products • Ten clinical candidates, including seven in immuno-oncology • Franchises targeting B7-H3 and PD-1 • ≥1 New IND projected …See details»
MacroGenics Provides Update on Corporate Progress and 2024 …
1 day ago ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, …See details»
Scott Jackson | Board of Directors | MacroGenics, Inc.
Mr. Jackson has served as a director since January 2017. Mr. Jackson served as Chief Executive Officer and as a member of the Board of Directors of Celator Pharmaceuticals, Inc. from April …See details»
MacroGenics Announces Leadership Transition
Oct 30, 2024 MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the …See details»
MacroGenics Provides Update on Corporate Progress and 2024 …
1 day ago MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based …See details»
AbbVie drops MacroGenics-partnered ADC in light of early data
Mar 8, 2024 MacroGenics worked with ImmunoGen, now part of AbbVie following a $10.1 billion deal, to advance the ADC to a phase 1 readout. ADAM9 is overexpressed in non-small cell …See details»
MacroGenics Announces Leadership Transition - Morningstar
Oct 30, 2024 MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the …See details»
MacroGenics, Inc. (MacroGenics, Inc.) - 药物管线_专利_临床试验_ …
了解MacroGenics, Inc. (MacroGenics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的55项临床试验, 117篇新闻和88篇文献，疾病领域:肿瘤，感染，免疫系统疾病，内分泌与代谢疾 …See details»
Events & Presentations | MacroGenics, Inc.
Jan 13, 2025 MacroGenics, Inc. Fourth Quarter 2022 Financial Results Conference Call. Listen to webcast. Feb 16 - Feb 18, 2023 ASCO-Genitourinary Cancers Symposium 2023 …See details»
Join Our Team – MacroGenics
Employees in every department can see firsthand how they contribute to the success of the organization. ... If you are an AGENCY or a SEARCH FIRM looking to partner with …See details»
Q4 2024 MacroGenics Inc Earnings Call - Yahoo Finance Canada
19 hours ago Good afternoon. We will begin the MacroGenics fourth quarter and full-year 2024 corporate progress and financial results conference call in just a moment. All participants are …See details»
MacroGenics at Barclays Conference: Strategic Insights on Pipeline …
On Wednesday, 12 March 2025, MacroGenics Inc. (NASDAQ: MGNX) participated in the Barclays 27th Annual Global Healthcare Conference. The discussion, led by biotech analyst …See details»
MacroGenics Inc. (MGNX) reports earnings - Quartz
2 days ago MacroGenics ended 2024 with $201.7 million in cash, cash equivalents, and marketable securities, and anticipates that its current resources will fund operations into the …See details»
MacroGenics to Participate in Upcoming Investor Conferences
Feb 27, 2025 MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody …See details»